Doctors were hopeful the drug, which was being tested in a large clinical trial by Novartis, was going to be a powerful new tool to fight heart disease.
An illustration of lipoprotein(a), a low-density lipoprotein. Every study short of a randomized clinical trial had indicated that the drug would lower Lp(a) and help protect people from heart disease.